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Effects of continual intermittent 
administration of parathyroid 
hormone on implant stability in the 
presence of osteoporosis: an in vivo 
study using resonance frequency 
analysis in a rabbit model
Objective: This study aimed to evaluate the effects of continual 
intermittent administration of parathyroid hormone (PTH) on implant stability 
in the presence of osteoporosis, using rabbit models. Material and Methods: 
Fifteen female New Zealand white rabbits underwent ovariectomy and were 
administered glucocorticoids to induce osteoporosis, following which they were 
?????????????????????????????????????????????????????????????????????????????
PTH for 4 weeks until implant placement (PTH1), while the second and third 
groups received PTH (PTH2) and saline (control), respectively, for 4 weeks 
before and after implant placement. After intermittent administration of PTH 
or saline, titanium implants were inserted into the left femoral epiphyses of all 
animals, and the implant stability quotient (ISQ) was measured immediately 
after placement to assess the primary stability and at 2 and 4 weeks after 
implant placement to assess osseointegration. At 4 weeks after implant 
placement, histological and histomorphometric evaluations were conducted 
and the bone area around the implant socket was measured as a ratio of the 
total bone area to the total tissue area. Results: Regarding primary stability, 
??????????????????????????????????????????????????????????????????????????
those for the control group (p<0.05). Concerning osseointegration, the ISQ 
?????????????????????????????????????????????????????????????????????????
for the PTH1 and control (p<0.05) groups. Histological assessments showed 
a thicker and more trabecular bone around the implant sockets in the PTH2 
specimens than in the PTH1 and control specimens. The bone area around the 
? ?????????????????????????????????????????????????????????????????????????
and control groups (p<0.05). Conclusions: Our results suggest that continual 
intermittent PTH administration before and after dental implant placement 
is effective for the achievement of favorable stability and osseointegration 
in the presence of osteoporosis.
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Introduction
Successful implant therapy depends on the 
achievement of favorable implant stability, which 
can be divided into primary stability and secondary 
stability or osseointegration9. Both primary stability 
and osseointegration are affected by different factors, 
including bone quantity and quality, implant design, 
and surgical protocols24. In particular, the most 
important factor is the condition of the bone at the 
site of implant placement19. Primary stability decreases 
at sites with a low bone density, which may result in 
implant failure25.
Osteoporosis is a skeletal disease that causes 
the systematic loss of bone regarding density and 
quantity. As mentioned above, the condition of 
the bone at the implant placement site is strongly 
correlated with the implant failure rate. Patients with 
osteoporosis who undergo implant treatment show less 
favorable outcomes compared with patients exhibiting 
healthy bone28. The most common secondary form 
of osteoporosis is that induced by glucocorticoid 
???????????????????????????????????????????????????
autoimmune disorders17. Glucocorticoids affect the 
bone quality mainly by decreasing bone formation 
by a decrease in osteoblastogenesis and an increase 
in osteoblast and osteocyte apoptosis. Therefore, 
glucocorticoid-induced osteoporosis is an unfavorable 
factor regarding implant stability. In a previous study, 
we showed that glucocorticoid-induced osteoporosis 
decreased the primary stability of implants and the 
mechanical strength of the femur in a rabbit model23. 
The phenomenon of poorly primary stability was 
caused by reduction of cortical bone thickness and 
mechanical strength.
Currently, the intermittent administration of 
parathyroid hormone (PTH) for enhancing bone 
formation and improving bone quantity is clinically 
approved. Some animal studies have reported 
that intermittent PTH administration is effective 
in promoting bone remodeling and increasing the 
trabecular bone mass10,11. PTH affects cancellous bone 
remodeling by promoting the formation of osteoblasts 
and suppressing their apoptosis2,16. Furthermore, it 
increases the thickness of not only trabecular bone, 
but also cortical bone15. Therefore, intermittent PTH 
administration can be effective in improving the bone 
density at the implant placement site and achieving 
favorable primary stability and osseointegration in 
patients with severe osteoporosis, including that 
induced by glucocorticoids. Corsini, et al.5 (2008) 
reported that intermittent PTH administration enhanced 
secondary stability in normal healthy rabbits. Almagro, 
et al.1 (2013) reported that osseointegration could be 
improved by intermittent PTH administration in rabbit 
models with osteoporosis.
In these studies, however, intermittent PTH 
administration was initiated after implant placement; 
furthermore, only secondary implant stability or 
osseointegration was evaluated. Therefore, the effects 
on primary stability remained unclear, considering the 
bone quality at the implant placement site was not 
improved by prior intermittent PTH administration. 
On the other hand, our previous study assessed 
the effects of intermittent PTH administration 
initiated before implant placement in rabbit models 
with osteoporosis21. Thus, the bone condition was 
improved before implant placement and favorable 
primary stability was achieved. However, secondary 
stability was not evaluated. Therefore, few studies 
have evaluated the effects of PTH therapy on 
osseointegration after the achievement of favorable 
primary stability. This study aimed to evaluate the 
effects of continual intermittent PTH administration 
before and after dental implant placement on primary 
stability and secondary stability in the presence of 
osteoporosis induced in rabbit models by ovariectomy 
and glucocorticoid administration.
Material and methods
Ethics
All animal experiments were conducted in 
accordance with the current version of the Japan Law 
on the Protection of Animals. This study was approved 
by the Research Facilities Committee (A16-3). All 
surgeries were performed under general anesthesia, 
and all efforts were made to minimize suffering during 
the experimental period.
Animals and experimental design
Fifteen 17-week-old female New Zealand White 
rabbits (3.0-3.5 kg body weight) were used in this 
study. The experimental design is shown in Figure 
1. All animals initially underwent ovariectomy, and, 
2 weeks later, they received intramuscular injections 
of methylprednisolone acetate (0.5 mg/kg/day) 
???????????????????????????????????????????????????????????????????????????? ??????????????????????????????????????????????????????????????????????????????????????????????????????????
rabbit model
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(Depo-Medrol®??????????????????????????????????????
4 consecutive weeks to induce osteoporosis3,4. Seven 
weeks after ovariectomy, the animals were divided into 
???????????????????????????????????????????????????
PTH (40 μg/day, 5 days/week) (Forteo®, Eli Lilly, 
Indianapolis, Indiana, USA) for 4 weeks (PTH1 group) 
until implant placement, then saline was administrated 
for 4 weeks. The second group received subcutaneous 
PTH for 4 weeks before and after implant placement 
(PTH2 group), and the third group received saline 
vehicle solution for 4 weeks before and after implant 
placement as osteoporosis (control group). The study 
end point was at 4 weeks after implant placement.
Implantation procedure
All procedures were performed under anesthesia with 
sodium pentobarbital (10 mg/kg, i.v.; Somnopentyl®, 
Kyoritsu Seiyaku Corporation, Chiyoda-ku, Tokyo, 
Japan). Implant sockets were prepared in the distal 
epiphysis (knee joint) of the left femur according to 
the GC protocol in the manufacturer’s instructions. 
?????????????????????????????????????????????? ??????
surgical system (iChiropro, Bien-air, Bienne, Bern, 
Switzerland) with a rotary speed not exceeding 800 
rpm was used for consecutive applications of a 2.0-
mm round drill, 2.0-mm twist drill, 3.0-mm pilot drill, 
3.0-mm twist drill, and countersink drill. Following the 
socket preparation procedures, implants (3.8 mm in 
diameter, 6.5mm in length; SETiO®, GC, Itabashi-ku, 
Tokyo, Japan) were inserted until the color indicator 
was level with the bone ridge (Figure 2). 
Measurement of the implant stability quotient 
(ISQ)
Resonance frequency analysis (RFA) was performed 
using an Osstell? device (Osstell AB, Gothenburg, 
??????? ????????????????????????? ???????????? ??????
Figure 1- Study design
Figure 2- Implant placement in a rabbit model of osteoporosis. 
The socket is created in the distal epiphysis (knee joint) of the 
left femur. After the knee joint was exposed, an implant surgical 
system with a rotary speed not exceeding 800 rpm was used for 
consecutive applications of a 2.0-mm round drill, 2.0-mm twist 
drill, 3.0-mm pilot drill, 3.0-mm twist drill, and countersink drill. 
Following the socket preparation procedures, implants were 
inserted until the color indicator was level with the bone ridge
Figure 3-? ???????? ?????????? ????????? ?????? ??????????????
Measurements are performed three times along the short and 
long axes to obtain mean values for the placed implant
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stability quotient (ISQ) immediately and 2 and 4 
weeks after implant placement for the evaluation of 
primary stability and secondary stability, respectively 
(Figure 3).
Measurements were performed three times from 
two different directions, and the values obtained for 
each implant were averaged. All measurements were 
obtained using procedures described in a previous 
study6,7.
Histological analysis
Four weeks after implant placement, the animals 
???????????????????????????? ?????????????????????
and tissue blocks were collected. The tissue blocks 
were trimmed and cut using a diamond saw system 
(400CS, EXAKT Apparatebau, Norderstedt, Land 
Schleswig-Holstein, Germany) at the center of the 
implant socket. The Observation section was set at 
????????????????????????????????????????????????? ???
?????????????????????????????????????????????????????
hydrochloride solution (KC-X®, FALMA, Shibuya-ku, 
Tokyo, Japan) for 5 days, dehydrated by a graded 
ethanol series, cleared with xylene, and embedded 
??? ????????? ????????? ????? ?? ????? ?????????? ?????
obtained from each block and stained with hematoxylin 
and eosin. Histological analysis was performed using 
light microscopy (BZ-9000, Keyence, Osaka, Osaka, 
Japan). Histological images were digitized and 
histomorphometrically analyzed using NIH ImageJ 
software (National Institutes of Health, Bethesda, 
Maryland, USA), and the bone area around the implant 
socket was measured as a ratio of the total bone area 
to the total tissue area. The regions of interest for the 
calculation of this ratio were set in the area around 
the implant socket, at 1.5 mm from its side and at 
half the vertical distance from the top of the implant 
shoulder. These regions were selected in accordance 
with previous studies21.
Statistical analysis
The data obtained were expressed as means 
± standard deviations. The values obtained were 
statistically analyzed using one-way analysis of variance 
and Tukey’s HSD test for multiple comparisons, with 
????????????????????????????
Results
Results of the RFA
Figure 4 shows the ISQ values obtained immediately 
after implant placement. The values for the PTH1 
(73.9±3.9) and PTH2 groups (75.6±7.1) were 
?????????????????????????????????????????????????????????
(47.7±12.7; p<0.05).
Figure 5 shows the ISQ values obtained 2 weeks 
after implant placement. The values for the control, 
PTH1, and PTH2 groups were 70.0±6.0, 74.4±2.5, and 
?????????? ???????????????????????????????????????????
between the control and PTH2 groups (p<0.05).
Figure 6 shows the ISQ values obtained 4 weeks 
after implant placement. At this point, the value for 
??????????????????????????????????????????????????
Figure 4-? ???????? ?????????? ????????? ?????? ??????? ? ??????????
?????? ? ?????? ??????????? ??? ?????????????? ?????? ???? ?????????
???????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
than the value for the control group
Figure 5-? ???????? ?????????? ????????? ?????? ?????????????????????
? ??????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????? ??????????????????????????????????????????????????????????????????????????????????????????????????????????
rabbit model
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than the values for both the control (68.1±5.1) and 
PTH1 (69.4±8.3) groups (p<0.05).
Histological observations and histomorphometric 
analyses
Figure 7 shows the findings of histological 
evaluation. In the control and PTH1 specimens, the 
trabecular bone structure was limited to the upper 
portion around the implant socket; the lower portion 
??? ????????????????????????????????????????????????
PTH2 specimen, on the other hand, trabecular bone 
structure was detected in the upper and lower portions 
around the implant socket (near the marrow).
The bone area around the implant socket was 
???????????????????????????????????????????????????
than in the PTH1 (30.8±7.7%) and control groups 
(25.5±3.8%; Table 1).
Discussion
Low bone density, such as that observed in 
patients with osteoporosis, results in poor primary 
implant stability because of decreased mechanical 
bone strength at the placement sites. Furthermore, 
osseointegration is barely achieved at such sites 
because of the suppression of bone remodeling. In 
this study, we found that continual intermittent PTH 
administration before and after implant placement can 
improve both primary stability and secondary stability, 
as determined by ISQ values.
????????????????????????????????????????????????????
suppressing bone formation through the inhibition 
of osteoblastogenesis and promotion of osteoblast 
and osteocyte apoptosis2,16. In our study, ISQ 
Figure 6-? ???????? ?????????? ????????? ?????? ?????????????????????
? ?????????????????????????????????????????????????????????????
??????????? ??????????????????????? ????? ?????????? ???? ?????????
and control group
Figure 7- Histological analyses of specimens from the (A) Control as osteoporosis. (B) PTH1: PTH administration for 4 weeks before 
implant placement. (C) PTH2: PTH administration for 4 weeks before and after implant placement. In the PTH1 and control specimens, 
????????????????????? ?????????????????????????????????????? ?????????????????????????????????????? ???????????????????????????????????
tissue. In the PTH2 specimen, trabecular bone is detected in the upper and lower portions (near the marrow) around the implant socket. 
(hematoxylin and eosin staining)
Bone area % (SD) Tukey’s HSD test
????????????? 25.5 (3.8)a ?????????
?????????? 30.8 (7.7)b ?????????
?????????? 41.7 (6.2)
SD: standard deviation
a??????????????????????????????????????????????????????????????????????
b???????????????????????????????????????????????????????????????????
Table 1- Ratio of bone area
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measurements were used to evaluate primary stability 
and secondary stability. Implant stability is considered 
an important measurement for evaluating the success 
of an implant therapy30. RFA is a noninvasive method 
for continuously measuring implant stability in clinical 
cases8,18, and we used an Osstell® device to perform 
it. ISQ values are derived on a scale from 1 to 100, 
and those for successfully stabilized implants are 
considered to range from 57 to 828. This device 
measures ISQ using RFA, which measures the emitting 
frequency by a vibration transducer attached to the 
??????????????????14??????????????????????????????
an effective amount of bone is surrounding the implant 
and whether the bone and implant surfaces have 
integrated or not12,26.
??? ???? ?????????? ??? ??????? ??? ???????????????
adaptation between the implant surface and the 
surrounding bone27. In this study, ISQ values for 
??? ?????????????? ?????????????????????????????????????
(4 weeks before implant placement) and PTH2 (4 weeks 
before and after implant placement) groups than for 
the control group. The ISQ value for the control group 
was only 47.7±12.7, which indicated unfavorable 
??? ???????????????????????????????????????????????????
of osteoblast differentiation and suppression of 
osteoclasts by intermittent PTH administration in poor 
????????????????? ??????????????????? ???????????????
our previous study21. In another study, bone density 
???? ????????????? ?????????? ?????? ???????????? ????
glucocorticoid administration, as assessed by dual-
energy X-ray analysis4. In addition, our previous 
study showed that the mechanical bone strength was 
lower in rabbit models with osteoporosis induced by 
ovariectomy and glucocorticoid administration than 
in a healthy rabbit model. Accordingly, we believe 
that the primary stability in both PTH groups of our 
study increased because of an improvement in the 
bone condition at the implant placement site caused 
by intermittent PTH administration before implant 
placement. The aspects consider that intermittent 
PTH administration before implant placement inhibits 
osteoclast activity and enhances osteoblast activity, 
hence the trabecular structure increase at the implant 
placement portion. Thus, primary stability of PTH1 and 
PTH2 groups was improved. 
??????????????????????????????????????????????????
as the integration between the implant surface and the 
surrounding bone. The newly formed bone and bone 
remodeling at the bone-implant interface and in the 
surrounding area correlate with RFA measurement18. 
Several studies have reported that the bone condition 
????????????????????????? ????????????????????????????
measurements are related to the supported length of 
the bone stiffness around the implant socket8,12,18,22. 
In our study, the ISQ value 4 weeks after implant 
placement was significantly higher for the PTH2 
group than for the other two groups. Histological 
assessments showed a thicker and more trabecular 
bone in the PTH2 specimens than in the PTH1 and 
control specimens. In the PTH2 group, newly formed 
bone was detected not only in the upper portion but 
also in the lower portion near the bone marrow. In 
addition, the implant socket could be clearly visualized 
in this group. In the other two groups, the newly 
formed bone was limited to the upper portion around 
the implant socket. Histomorphological analyses 
indicated that the bone area around the implant socket 
????????????????????????? ??? ???????????????????? ???
the PTH1 and control groups. The ISQ is considered 
to increase in condition to the stiffness of the bone-
implant interface13,26.
Also, Miyamoto, et al.20??????????????????????????????
correlation detected between the ISQ and bone cortical 
thickness. This result was in accordance with the ISQ 
values at 4 weeks, which were high for the PTH group 
because of new bone formation around the placed 
implants, caused by the effects of PTH administration 
during the healing period. The aspects consider 
that intermittent PTH administration after implant 
placement accelerate bone formation around the 
placed implant enhances osteoblast activity. Thus, the 
secondary stability of PTH2 group was increased. We 
??????????????????????????????????????????????????????
the PTH1 and PTH2 groups at 2 weeks after implant 
placement. Castañeda, et al.3 (2008) reported that the 
effects of glucocorticoids  persisted for more than 3 
months after discontinuation in a rabbit study. Thus, 
we considered that the behavior of glucocorticoids 
persists during the term in this study. On the other 
hand, the half-life of PTH is relatively short. Therefore, 
we believe that the bone remodeling caused by PTH 
administration continues for 2 weeks and ceases at 
4 weeks. We observed favorable primary stability in 
the PTH1 group, although secondary stability was 
?? ????? ??? ????? ??? ???? ???????? ??????? ??????????????
indicate that continual intermittent administration of 
PTH after implant placement is necessary to promote 
osseointegration. Various reports have documented 
???????????????????????????????????????????????????????????????????????????? ??????????????????????????????????????????????????????????????????????????????????????????????????????????
rabbit model
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the appropriate dosage of PTH for achieving such an 
effect5,29. In our study, the PTH dose rate was set at 
??????? ???????????????????????? ?????????????????
is within the range used for in vivo rabbit studies (15-
??????????????? ??????????3,21.
In conclusion, the results of our study suggest that 
continual intermittent PTH administration is effective 
for achieving favorable primary and secondary stability 
in the presence of osteoporosis. It is the authors’ 
intention to conduct further studies comparing normal 
healthy models to investigate the detailed effects of 
PTH on implant stability.
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